[Evidence for osteoporosis treatment using PTH (1-34) daily subcutaneous injection].
[Evidence for osteoporosis treatment using PTH (1-34) daily subcutaneous injection].
复制标题
DOI：
--
复制
发表时间：
2012-03
期刊：
影响因子：
--
通讯作者：
Takanori Yamamoto;Etsuro Hamaya;H. Sowa
中科院分区：
文献类型：
--
作者：
Takanori Yamamoto;Etsuro Hamaya;H. Sowa
PTH（1-34）每日皮下注射是一种骨合成代谢剂。该产品已在全球80多个国家（包括欧洲和美国）获得批准，并于2010年7月在日本获得批准。在日本，用这种药剂治疗的患者人数超过2万，在全世界约有100万。在非临床研究中，特立帕鲁肽显示出在现有药物中未观察到的独特的骨形成刺激作用。国内外的临床研究表明，替普瑞酮具有较强的增加骨密度、促进骨微结构重建和抑制骨折发生的作用。此外，它可以通过刺激骨形成来增加BMD，而不管先前治疗的性质或对先前治疗的反应是否存在。有了这些特点，特立帕鲁肽有望成为治疗骨质疏松症骨折高危患者的一线药物。
PTH (1-34) daily subcutaneous injection is a bone anabolic agent. It has already been approved in more than 80 countries over the world (including Europe and United States) and in Japan on Jul 2010. The number of patients treated with this agent is more than 20 thousand in Japan and about one million over the world. In nonclinical studies, teriparatide was shown to have a unique bone formation-stimulating effect not seen in existing drugs. In domestic and overseas clinical studies, teriparatide was shown to have strong effects in increasing BMD, promoting remodeling of bone microstructure and suppressing the onset of fracture. Furthermore, it can increase BMD through stimulation of bone formation regardless of the nature of prior treatment or the presence/absence of responses to prior treatment. With these features, teriparatide is expected to serve as a first-line drug for management of patients with osteoporosis at high risk for fracture.